Andere Sprachen Perspective Therapeutics, Inc.

Aktien

A40EDR

US46489V3024

CATX

Realtime-Estimate Cboe BZX Andere Börsenplätze 21:12:05 26.06.2024			% 5 Tage	% 1. Jan.
9,355 ^USD	-2,04 %		-13,99 %	+127,86 %

12.06.	Sektor-Update: Aktien des Gesundheitswesens geben am späten Nachmittag nach	MT
12.06.	Sektor-Update: Aktien des Gesundheitswesens am Mittwochnachmittag schwächer	MT

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Sector Update: Health Care Stocks Ease Late Afternoon	12.06.
Sector Update: Health Care Stocks Softer Wednesday Afternoon	12.06.
Perspective Therapeutics to Join Russell 3000 Index on July 1	12.06.
Perspective Therapeutics Announces Inclusion in the Russell 3000® Index	12.06.
Perspective Therapeutics to Reverse Split Common Shares	11.06.
Perspective Therapeutics Announces 1-for-10 Reverse Stock Split	11.06.
Perspective Therapeutics Announces 1-for-10 Reverse Stock Split	11.06.
Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting	10.06.
Perspective Therapeutics Prices $80 Million Share, Warrant Offering	24.05.
Perspective Therapeutics Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants	24.05.
Perspective Therapeutics to Present at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting 2024	21.05.
Perspective Therapeutics to Present at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2024	20.05.
Perspective Therapeutics Swings to Loss in Q1, Revenue Rises	15.05.
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 Results	15.05.
Perspective Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15.05.
Perspective Therapeutics to Participate at Upcoming May Investor Conferences	06.05.
Perspective Therapeutics to Participate at Upcoming May Investor Conferences	03.05.
Perspective Therapeutics to Provide Recent Business Highlights and Report First Quarter 2024 Financial Results	02.05.
Perspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT-α-NET in NETs	30.04.
Perspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT-α-NET in NETs	30.04.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Perspective Therapeutics, Inc.

Aktien

A40EDR

US46489V3024

CATX

Andere Sprachen

Filter